Previous 10 | Next 10 |
– CBP-174 in development for pruritus associated with allergic and inflammatory skin diseases, including atopic dermatitis, was observed to be safe and well-tolerated – SAN DIEGO and TAICANG, SUZHOU, China, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limit...
Gainers: TOP Financial Group ( TOP ) +105% . Bonso Electronics International ( BNSO ) +79% . Helbiz ( HLBZ ) +71% . Intelligent Living Application Group ( ILAG ) +63% . Karuna Therapeutics ( KRTX ) +61% . CinCor Pharma ( CI...
Qiming Venture Partners closed two new China healthcare and technology funds with $3.2 billion in fresh capital, both of them at their hard cap limits. Suzhou CStone Pharma announced that Gavreto® (pralsetinib) was approved in Hong Kong to treat adult patients with RET fusion-pos...
— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled — — Expected Timing for Potential NDA Approval in China Remains Unchanged and is Targeted for 2025 — SAN DIEGO and TAICANG, SUZHOU, China, July 11, 2022 (GLO...
3 Hot Penny Stocks to Add to Your Watchlist Right Now While June 29th, 2022 was a rather flat trading day for penny stocks and blue chips, there is a lot for investors to look forward to right now. For example, in 2022 we have seen many penny stocks fall to very low levels. And ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com With the start of another day comes our breakdown of the biggest pre-market stock movers for Wednesday! We’ve got offering news, earnings, a buyout offer, and more to go o...
Connect Biopharma (NASDAQ:CNTB) stated Friday that it had got a notification from Nasdaq that the company was not in compliance with a listing rule on $1 minimum bid price requirement. The company has 180 days, or until Dec. 13, to regain compliance Press Release For further detai...
SAN DIEGO, CA and TAICANG, SUZHOU, China, June 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”) announced on June 16, 2022, Connect Biopharma Holdings Limited (the “Company”) received a letter f...
SAN DIEGO, CA and TAICANG, SUZHOU, China, June 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inf...
SAN DIEGO, CA and TAICANG, China, May 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflamma...
News, Short Squeeze, Breakout and More Instantly...
Connect Biopharma Holdings Limited Company Name:
CNTB Stock Symbol:
NASDAQ Market:
Connect Biopharma Holdings Limited Website:
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases thr...
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases thr...
Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24 Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24 End of Phase 2 (EoP2) meeting i...